Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 3
2001 1
2002 1
2003 2
2004 3
2005 1
2006 3
2007 4
2008 5
2009 4
2010 4
2011 3
2012 6
2013 10
2014 9
2015 9
2016 6
2017 6
2018 11
2019 12
2020 3
2021 13
2022 5
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. Among authors: ataga ki. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E. Howard J, et al. Among authors: ataga ki. Lancet Haematol. 2021 May;8(5):e323-e333. doi: 10.1016/S2352-3026(21)00059-4. Epub 2021 Apr 7. Lancet Haematol. 2021. PMID: 33838113 Clinical Trial.
Using disease-modifying therapies in sickle cell disease.
Rai P, Ataga KI. Rai P, et al. Among authors: ataga ki. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):519-531. doi: 10.1182/hematology.2023000485. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066905
The glomerulopathy of sickle cell disease.
Ataga KI, Derebail VK, Archer DR. Ataga KI, et al. Am J Hematol. 2014 Sep;89(9):907-14. doi: 10.1002/ajh.23762. Epub 2014 Jun 19. Am J Hematol. 2014. PMID: 24840607 Free PMC article. Review.
Sickle Cardiomyopathy: The Missing Forest in the Trees.
Caughey MC, Ataga KI, Hinderliter AL. Caughey MC, et al. Among authors: ataga ki. JACC Cardiovasc Imaging. 2016 Mar;9(3):253-4. doi: 10.1016/j.jcmg.2015.06.024. Epub 2016 Feb 17. JACC Cardiovasc Imaging. 2016. PMID: 26897663 Free article. No abstract available.
Drug Therapies for the Management of Sickle Cell Disease.
Rai P, Ataga KI. Rai P, et al. Among authors: ataga ki. F1000Res. 2020 Jun 11;9:F1000 Faculty Rev-592. doi: 10.12688/f1000research.22433.1. eCollection 2020. F1000Res. 2020. PMID: 32765834 Free PMC article. Review.
128 results